RU2018120183A - Способы ингибирования превращения холина в триметиламин (тма) - Google Patents

Способы ингибирования превращения холина в триметиламин (тма) Download PDF

Info

Publication number
RU2018120183A
RU2018120183A RU2018120183A RU2018120183A RU2018120183A RU 2018120183 A RU2018120183 A RU 2018120183A RU 2018120183 A RU2018120183 A RU 2018120183A RU 2018120183 A RU2018120183 A RU 2018120183A RU 2018120183 A RU2018120183 A RU 2018120183A
Authority
RU
Russia
Prior art keywords
isothiocyanate
oil
compound
tma
trimethylamine
Prior art date
Application number
RU2018120183A
Other languages
English (en)
Other versions
RU2018120183A3 (ru
Inventor
Стэнли Леон ХАЗЕН
Хосе Карлос ГАРЦИЯ-ГАРСИЯ
Джордж Франклин ГЕРБЕРИК
Джон Аугуст УОС
Дэвид Томас СТАНТОН
Томас Альфред ИНГЛИН
Майкл РЕЙЛЛИ
Анжела Джейн ДЕУТЧ
Джоди Мишель РИИД
Дэвид Блаир КОДЫ
Original Assignee
Дзе Проктер Энд Гэмбл Компани
Дзе Кливленд Клиник Фоундэйшион
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Проктер Энд Гэмбл Компани, Дзе Кливленд Клиник Фоундэйшион filed Critical Дзе Проктер Энд Гэмбл Компани
Publication of RU2018120183A3 publication Critical patent/RU2018120183A3/ru
Publication of RU2018120183A publication Critical patent/RU2018120183A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (16)

1. Способ ингибирования превращения холина в триметиламин (ТМА) бактерией, включающий приведение бактерии в контакт с соединением, представленным формулой (I):
Figure 00000001
Формула (I),
где R1 выбирают из цианата, изоцианата, тиоцианата, изотиоцианата, нитрила, изонитрила или сульфгидрила;
n’ выбирают из 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10; и
R2 выбирают из алкила, разветвленного алкила, гетероалкила, циклоалкила, гетероциклоалкила, арила или замещенного карбонила;
причем, если R2 представляет собой фенил, R2 замещен 0, 1 или 2 группами, независимо выбранными из алкила, разветвленного алкила, гетероалкила, циклоалкила, гетероциклоалкила, галогена или арила;
причем, если R2 представляет собой гетероалкил или гетероциклоалкил, гетероатом (-ы) не является (-ются) S;
при этом, если n’ равно 2, R2 не является незамещенным фенилом; и
включая любые их приемлемые соли или сольваты.
2. Способ по п. 1, в котором R1 представляет собой изотиоцианат, причем предпочтительно соединение представляет собой втор-изотиоцианат или этилизотиоцианат.
3. Способ по п. 2, в котором n’ равно 0, причем предпочтительно соединение выбирают из группы, состоящей из бензоилизотиоцианата, 4-бромфенилизотиоцианата, 4-(метилтио)фенилизотиоцианата, 1-нафтилизотиоцианата, 3-метоксифенилизотиоцианата и 4-метоксифенилизотиоцианата.
4. Способ по п. 2, в котором n’ равно по меньшей мере 1, причем предпочтительно соединение представляет собой по меньшей мере одно из бензилизотиоцианата, 3-диэтиламинопропилизотиоцианата, N-Boc-4-изотиоцианатобутиламина, 3-(4-морфолино)пропилизотиоцианата, 2-(4-морфолино)этилизотиоцианата и 2-пиперидиноэтилизотиоцианата.
5. Способ по любому из пп. 1–4, дополнительно включающий приведение бактерии в контакт со вторым агентом, который представляет собой по меньшей мере одно из масла омега-3, салициловой кислоты, диметилбутанола, чесночного масла, оливкового масла, масла криля, кофермента Q-10, пробиотика, пребиотика, пищевых волокон, шелухи семян подорожника, солей висмута, фитостеролов, масла виноградных косточек, экстракта зеленого чая, витамина D, антиоксиданта, куркумы, куркумина, ресвератрола, активированного угля и хлорофиллина меди.
6. Способ по любому из пп. 1–5, в котором превращение холина в триметиламин (ТМА) ингибируется на от приблизительно 1% до приблизительно 100%.
7. Способ по любому из пп. 1–6, в котором бактерия представляет собой по меньшей мере одну из Proteus mirabilis, Desulfovibrio alaskensis, Clostridium ljungdahlii, C. scindens, C. aldenense, Collinsella tanakaei, Anaerococcus vaginalis, Streptococcus dysgalactiae, Desultitobacterium hafniense, Klebsiella variicola, K. pneumonia или Escherichia coli.
RU2018120183A 2015-12-01 2016-12-01 Способы ингибирования превращения холина в триметиламин (тма) RU2018120183A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562261645P 2015-12-01 2015-12-01
US201562261662P 2015-12-01 2015-12-01
US62/261,662 2015-12-01
US62/261,645 2015-12-01
US201662356422P 2016-06-29 2016-06-29
US62/356,422 2016-06-29
PCT/US2016/064339 WO2017095993A1 (en) 2015-12-01 2016-12-01 Methods for inhibiting conversion of choline to trimethylamine (tma)

Publications (2)

Publication Number Publication Date
RU2018120183A3 RU2018120183A3 (ru) 2020-01-10
RU2018120183A true RU2018120183A (ru) 2020-01-10

Family

ID=57680518

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2018120183A RU2018120183A (ru) 2015-12-01 2016-12-01 Способы ингибирования превращения холина в триметиламин (тма)
RU2018116864A RU2018116864A (ru) 2015-12-01 2016-12-01 Соединения и способы ингибирования продукции триметиламина
RU2018120189A RU2018120189A (ru) 2015-12-01 2016-12-01 Способы ингибирования превращения карнитина в триметиламин (ТМА)

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2018116864A RU2018116864A (ru) 2015-12-01 2016-12-01 Соединения и способы ингибирования продукции триметиламина
RU2018120189A RU2018120189A (ru) 2015-12-01 2016-12-01 Способы ингибирования превращения карнитина в триметиламин (ТМА)

Country Status (9)

Country Link
US (3) US10213407B2 (ru)
EP (3) EP3383376B1 (ru)
CN (3) CN108601753A (ru)
AU (4) AU2016365314A1 (ru)
BR (3) BR112018011210A2 (ru)
CA (3) CA3005760C (ru)
PL (1) PL3383376T3 (ru)
RU (3) RU2018120183A (ru)
WO (3) WO2017095995A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3383376T3 (pl) 2015-12-01 2021-10-04 The Procter & Gamble Company Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
US11298334B2 (en) * 2016-04-22 2022-04-12 Jc (Wuxi) Company, Inc. Use of isothiocyanate compounds
BR112018076765A2 (pt) 2016-06-29 2019-04-02 The Procter & Gamble Company métodos para inibir a conversão de colina em trimetilamina (tma)
CA3066620A1 (en) * 2017-06-08 2018-12-13 Allergyintellect, Inc Vitamin d compounds and methods of using the same
EP4299064A3 (en) * 2017-06-19 2024-03-20 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the tma/fmo3/tmao pathway
CN111163761A (zh) * 2017-08-14 2020-05-15 普梭梅根公司 与三甲胺和/或三甲胺-n-氧化物相关的靶向药物
AU2018345749B2 (en) * 2017-10-02 2021-03-11 The Cleveland Clinic Foundation Methods for inhibiting conversion of choline to trimethylamine (TMA)
BR112020006108A2 (pt) 2017-10-02 2020-09-24 The Procter & Gamble Company métodos para inibir a conversão de colina em trimetilamina (tma)
BR112020006121B1 (pt) 2017-10-02 2022-05-24 The Cleveland Clinic Foundation Métodos para inibir a conversão de colina em trimetilamina (tma)
CN108976485B (zh) * 2018-01-22 2020-11-03 内蒙古大学 一种凝胶多糖与稀土复合的柔性发光薄膜及其制备方法
EP3746066A4 (en) * 2018-02-01 2023-05-10 The Cleveland Clinic Foundation DISEASE DETECTION AND TREATMENT BASED ON TRIMETHYL-LYSINE LEVELS
US20200138887A1 (en) 2018-11-06 2020-05-07 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (tma)
US11331280B2 (en) 2018-11-06 2022-05-17 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (TMA)
CA3121513A1 (en) * 2018-12-06 2020-06-11 Senda Biosciences, Inc. Decarboxylase inhibitors for treating parkinson's disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242863A (en) * 1968-05-10 1971-08-18 Pharmacia As 2,3-DIHYDRO-5H-THIAZOLO[2,3-b]QUINAZOLINES AND PROCESSES FOR THE PREPARATION THEREOF
US4335141A (en) 1979-12-26 1982-06-15 Merck & Co., Inc. 2-Substituted-aminopropene-and propanenitrile antimicrobial and anti-inflammatory agents
US4874788A (en) 1985-10-01 1989-10-17 Ethyl Corporation Quaternary ammonium compounds
US5547677A (en) 1994-05-20 1996-08-20 Novavax, Inc. Antimicrobial oil-in-water emulsions
CA2337428A1 (en) 1998-08-21 2000-03-02 Anne Schuwey Thermal- and photoinitiated radical polymerization in the presence of an addition fragmentation agent
WO2002016366A1 (fr) 2000-08-23 2002-02-28 Itoi Textile Co., Ltd Chlorophylline de cuivre ou de fer sodee, pate, solution aqueuse de pigment, file de papier et procede de production de celui-ci
JP4099012B2 (ja) 2002-07-12 2008-06-11 富士フイルム株式会社 画像形成材料
JP4798973B2 (ja) * 2004-08-04 2011-10-19 丸善製薬株式会社 抗菌用組成物
US20070199890A1 (en) 2006-02-27 2007-08-30 Agion Technologies, Inc. Antimicrobial activated carbon and use thereof
US8859798B2 (en) 2006-07-06 2014-10-14 Rutgers, The State University Of New Jersey Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
EP2081953A2 (en) * 2006-08-17 2009-07-29 The UAB Research Foundation Immunogenic pcpa polypeptides and uses thereof
US9423405B2 (en) 2007-12-05 2016-08-23 The Cleveland Clinic Foundation Trimethylamine compounds as risk predictors of cardiovascular disease
WO2010084661A1 (ja) 2009-01-23 2010-07-29 金印株式会社 イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
CA2790371C (en) * 2009-05-28 2020-09-01 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2010140902A1 (en) * 2009-06-02 2010-12-09 Mark Hampton Inhibitors of macrophage migration inhibitory factor
GB0922505D0 (en) * 2009-12-23 2010-02-10 Plant Bioscience Ltd Use
US20120225020A1 (en) 2011-02-24 2012-09-06 Chekmenev Eduard Y Unsaturated choline analogs and chemical synthesis thereof
BR112014031086A2 (pt) 2012-06-11 2017-06-27 Cleveland Clinic Found tratamento e prevenção de doenças cardiovasculares e trombose
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CA2963422A1 (en) 2014-10-03 2016-04-07 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
PL3383376T3 (pl) 2015-12-01 2021-10-04 The Procter & Gamble Company Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
BR112018076765A2 (pt) 2016-06-29 2019-04-02 The Procter & Gamble Company métodos para inibir a conversão de colina em trimetilamina (tma)

Also Published As

Publication number Publication date
PL3383376T3 (pl) 2021-10-04
WO2017095995A1 (en) 2017-06-08
RU2018120189A (ru) 2020-01-10
BR112018011210A2 (pt) 2018-11-21
US20170151250A1 (en) 2017-06-01
RU2018116864A (ru) 2020-01-09
RU2018120189A3 (ru) 2020-01-10
AU2019280094A1 (en) 2020-01-16
EP3383377A1 (en) 2018-10-10
CA3005760C (en) 2019-10-08
EP3383377B1 (en) 2024-04-17
EP3383376A1 (en) 2018-10-10
CA3007081C (en) 2022-03-29
AU2019280094B2 (en) 2021-09-16
EP3383376B1 (en) 2021-05-12
AU2016365316B2 (en) 2019-11-07
CN108601753A (zh) 2018-09-28
AU2016365316A1 (en) 2018-06-21
RU2018120183A3 (ru) 2020-01-10
US10213407B2 (en) 2019-02-26
US20170151208A1 (en) 2017-06-01
US10780072B2 (en) 2020-09-22
CN108601754A (zh) 2018-09-28
EP3383378B1 (en) 2024-04-17
RU2018116864A3 (ru) 2020-01-09
AU2016365314A1 (en) 2018-06-21
CN108472267A (zh) 2018-08-31
CA3007061C (en) 2021-03-16
CA3005760A1 (en) 2017-06-08
US10786479B2 (en) 2020-09-29
US20170152222A1 (en) 2017-06-01
EP3383378A1 (en) 2018-10-10
AU2016362298A1 (en) 2018-05-31
WO2017095975A1 (en) 2017-06-08
BR112018011216A2 (pt) 2018-11-21
CN108472267B (zh) 2021-12-24
CA3007061A1 (en) 2017-06-08
BR112018010873A2 (pt) 2019-04-30
CA3007081A1 (en) 2017-06-08
WO2017095993A1 (en) 2017-06-08
AU2016362298B2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
RU2018120183A (ru) Способы ингибирования превращения холина в триметиламин (тма)
TN2019000281A1 (en) Ferroportin-inhibitor salts
EP3964516A4 (en) OXAAZACHUINAZOLINE-7( 8H)-KETONE COMPOUND, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL APPLICATION
CA2990277C (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
MX2021015106A (es) Inhibidores de ferroportina novedosos.
NZ739429A (en) Liquid pharmaceutical compositions comprising sglt-2 inhibitors
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
PE20171517A1 (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac 8
WO2016094726A3 (en) Compounds that modulate fatty acid receptor activity and pet food products containing the same
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
AR099376A1 (es) Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
NZ721645A (en) Compounds for use as gpr120 agonists
RU2018142330A (ru) Способы ингибирования превращения холина в триметиламин (тма)
EA202090259A1 (ru) Новые гетероариламидные производные как селективные ингибиторы гистондеацетилаз 1 и/или 2 (hdac1-2)
AR095098A1 (es) Derivado de azol benceno con actividad inhibidora de xantina oxidasa
MY190361A (en) 2-acylaminothiazole derivative or salt thereof
WO2014147182A3 (en) Substituted n-biphenyl-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-biphenyl-carboxamides and their use as inhibitors of the wnt signalling pathway
EA201390872A1 (ru) Оставляемые на коже после нанесения нетвердые улучшающие состояние кожи композиции, содержащие 12-гидроксистеариновую кислоту и этоксилированное гидрогенизированное касторовое масло
WO2020021108A3 (en) Nucleic acids for inhibiting expression of tmprss6 and iron chelators
EP3620457A4 (en) COMPOUND DERIVED FROM PYRIMIDINE, OPTICAL ISOMER, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING A TYRO 3-RELATED DISEASE, CONSIDERING IT AS AN ACTIVE INGREDIENT
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2019006861A (es) Composicion basada en compuestos de tiosulfinato y/o tiosulfonato para su uso en la prevencion de infecciones bacterianas en animales acuaticos.
MX2018010801A (es) Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos.
BR112013000042A2 (pt) composto para inibição da fosfodiesterase tipo 5 e método de preparação do mesmo
NZ599722A (en) Amidoacetonitrile compounds having pesticidal activity

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200806